Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors

N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC50 = 2 nM) and T. brucei (EC50 = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.

[1]  A Vagin,et al.  An approach to multi-copy search in molecular replacement. , 2000, Acta crystallographica. Section D, Biological crystallography.

[2]  J. Gordon,et al.  Scanning Alanine Mutagenesis and De-peptidization of a Candida albicans Myristoyl-CoA:ProteinN-Myristoyltransferase Octapeptide Substrate Reveals Three Elements Critical for Molecular Recognition* , 1997, The Journal of Biological Chemistry.

[3]  D. Goulding,et al.  ARL1 has an essential role in Trypanosoma brucei. , 2005, Biochemical Society transactions.

[4]  J. Gordon,et al.  Conformationally constrained [p-(omega-aminoalkyl)phenacetyl]-L-seryl-L-lysyl dipeptide amides as potent peptidomimetic inhibitors of Candida albicans and human myristoyl-CoA:protein N-myristoyl transferase. , 1997, Journal of medicinal chemistry.

[5]  Ian H. Gilbert,et al.  N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness , 2010, Nature.

[6]  K. Gull,et al.  CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. , 2001, Molecular and biochemical parasitology.

[7]  Sebastian Maurer-Stroh,et al.  N-terminal N-myristoylation of proteins: refinement of the sequence motif and its taxon-specific differences. , 2002, Journal of molecular biology.

[8]  M. Phillips,et al.  State of the art in African trypanosome drug discovery. , 2011, Current topics in medicinal chemistry.

[9]  I. Gilbert,et al.  Target assessment for antiparasitic drug discovery. , 2007, Trends in parasitology.

[10]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[11]  J. Lodge,et al.  Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity. , 1997, Journal of medicinal chemistry.

[12]  Masataka Nakamura,et al.  FTR1335 is a novel synthetic inhibitor of Candida albicans N-myristoyltransferase with fungicidal activity. , 2005, Biological & pharmaceutical bulletin.

[13]  R. Kaminsky,et al.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. , 1997, Acta tropica.

[14]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[15]  H Hirumi,et al.  Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. , 1989, The Journal of parasitology.

[16]  Katherine A Brown,et al.  Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. , 2003, Molecular and biochemical parasitology.

[17]  M. Ferguson,et al.  Myristoyl-CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects , 2010, Molecular and biochemical parasitology.

[18]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[19]  K. Nakazawa,et al.  Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure. , 2005, Bioorganic & medicinal chemistry.

[20]  Chick C. Wilson,et al.  Using small molecule crystal structure data to obtain information about sulfonamide conformation. , 2008, Acta crystallographica. Section B, Structural science.

[21]  K. Kawasaki,et al.  Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase. , 2003, Bioorganic & medicinal chemistry.

[22]  C. Mcwherter,et al.  Replacements for lysine in l-seryl-l-lysyl dipeptide amide inhibitors of candida albicans myristoyl-CoA:protein N-myristoyltransferase , 1997 .

[23]  J. Gordon,et al.  Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: protein N-myristoyltransferase: a new approach to antifungal therapy. , 1997, Biopolymers.

[24]  J. Gordon,et al.  Design and syntheses of potent and selective dipeptide inhibitors of Candida albicans myristoyl-CoA:protein N-myristoyltransferase. , 1995, Journal of medicinal chemistry.

[25]  S. Niizuma,et al.  Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3. , 2003, Bioorganic & medicinal chemistry letters.

[26]  K. Kawasaki,et al.  Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 1. , 2001, Bioorganic & medicinal chemistry letters.

[27]  K. Brown,et al.  Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. , 2006, The Biochemical journal.

[28]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[29]  Joseph W. Polli,et al.  Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor , 1999, Pharmaceutical Research.

[30]  A. Holder,et al.  N‐Myristoyltransferase: a Prospective Drug Target for Protozoan Parasites , 2008, ChemMedChem.

[31]  Daniel James,et al.  Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases , 2007, ChemMedChem.

[32]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.